← Back to Search

Radiotracer

11C-M503 PET for Tauopathies

Q: What specific criteria should be considered when selecting participants for this research endeavor?

Candidates eligible for participation in this clinical trial must be aged between 40 and 85 years old and have been diagnosed with tauopathies. The study aims to enroll approximately 70 individuals.

Q: What is the current number of individuals being recruited for participation in this research investigation?

Indeed, information from clinicaltrials.gov reveals that this particular research study is actively pursuing suitable candidates. The trial was initially made public on February 16th, 2024 and most recently revised on March 4th, 2024. Approximately 70 participants are being sought at a single site for enrollment in the trial.

Q: Is the enrollment for this research study currently open?

Yes, information provided on clinicaltrials.gov confirms the ongoing recruitment for this study. Initially shared on February 16th, 2024, and last revised on March 4th, 2024. The research aims to enroll 70 volunteers at a single site.

Q: Are elderly individuals above the age of 70 eligible to participate in this clinical trial?

Eligible participants for this research study must be above 40 years of age and below 85 years of age.

Phase < 1

Recruiting

Research Sponsored by University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 weeks

Awards & highlights

Study Summary

This trial aims to study a radiotracer called 11C-M503 to see how it moves in the body and reaches the brain in people with Parkinson's disease. They want to measure a protein

Who is the study for?

This trial is for people with tauopathies like Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). It also includes healthy volunteers without Parkinsonism. Participants must meet specific criteria set by the study, which are not detailed here.Check my eligibility

What is being tested?

The study tests a new radiotracer called 11C-M503 using brain scans like MRI and PET to see how it tracks abnormal alpha-synuclein in the brain. The goal is to compare its uptake in PD, MSA, PSP patients versus non-Parkinsonism volunteers across several research centers.See study design

What are the potential side effects?

Potential side effects are not specified but may include typical risks associated with MRI and PET scans such as discomfort from lying still, reactions to contrast agents used during imaging, or anxiety from being in a confined space.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Organ Biodistribution or Dosimetry

PET Uptake of Tracer

Secondary outcome measures

Adverse Events

Trial Design

1Treatment groups

Experimental Treatment

Group I: 11C-M503 PETExperimental Treatment4 Interventions

Participants will undergo 11C-M503 PET scan, they may also have a brain MRI and Amyloid PET scan as well as neurological assessments.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Neurological assessments

2021

N/A

~120

Brain MRI

2013

Completed Phase 4

~870

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor

2,005 Previous Clinical Trials

42,882,217 Total Patients Enrolled

2 Trials studying Tauopathies

124 Patients Enrolled for Tauopathies

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What specific criteria should be considered when selecting participants for this research endeavor?

"Candidates eligible for participation in this clinical trial must be aged between 40 and 85 years old and have been diagnosed with tauopathies. The study aims to enroll approximately 70 individuals."

Answered by AI

What is the current number of individuals being recruited for participation in this research investigation?

"Indeed, information from clinicaltrials.gov reveals that this particular research study is actively pursuing suitable candidates. The trial was initially made public on February 16th, 2024 and most recently revised on March 4th, 2024. Approximately 70 participants are being sought at a single site for enrollment in the trial."

Answered by AI

Is the enrollment for this research study currently open?

"Yes, information provided on clinicaltrials.gov confirms the ongoing recruitment for this study. Initially shared on February 16th, 2024, and last revised on March 4th, 2024. The research aims to enroll 70 volunteers at a single site."

Answered by AI